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ABSTRACT
It is accepted that an effective prophylactic HIV-1 vaccine is likely to have the greatest impact on viral transmission rates. As pre-
vious reports have implicated DNA-priming, protein boost regimens to be efficient activators of humoral responses, we sought
to optimize this regimen to further augment vaccine immunogenicity. Here we evaluated single versus concurrent intradermal
(i.d.) and intramuscular (i.m.) vaccinations as a DNA-priming strategy for their abilities to elicit humoral and cellular responses
against a model HIV-1 vaccine antigen, CN54-gp140. To further augment vaccine-elicited T and B cell responses, we enhanced
cellular transfection with electroporation and then boosted the DNA-primed responses with homologous protein delivered sub-
cutaneously (s.c.), intranasally (i.n.), i.m., or transcutaneously (t.c.). In mice, the concurrent priming regimen resulted in signifi-
cantly elevated gamma interferon T cell responses and high-avidity antigen-specific IgG B cell responses, a hallmark of B cell
maturation. Protein boosting of the concurrent DNA strategy further enhanced IgG concentrations but had little impact on T
cell reactivity. Interestingly protein boosting by the subcutaneous route increased antibody avidity to a greater extent than pro-
tein boosting by either the i.m., i.n., or t.c. route, suggesting that this route may be preferential for driving B cell maturation.
Using an alternative and larger animal model, the rabbit, we found the concurrent DNA-priming strategy followed by s.c. pro-
tein boosting to again be capable of eliciting high-avidity humoral responses and to also be able to neutralize HIV-1 pseudovi-
ruses from diverse clades (clades A, B, and C). Taken together, we show that concurrent multiple-route DNA vaccinations induce
strong cellular immunity, in addition to potent and high-avidity humoral immune responses.
IMPORTANCE
The route of vaccination has profound effects on prevailing immune responses.Due to the insufficient immunogenicity and protection
of currentDNAdelivery strategies, we evaluated concurrentDNAdelivery via simultaneous administration of plasmidDNAby the
i.m. and i.d. routes. The rationale behind this studywas to provide clear evidence of the utility of concurrent vaccinations for an up-
coming human clinical trial. Furthermore, thisworkwill guide future preclinical studies by evaluating the use ofmodel antigens and
plasmids for prime-boost strategies. This paperwill be of interest not only to virologists and vaccinologistsworking in theHIVfield
but also to researchersworking in other viral vaccine settings and, critically, to thewider field of vaccine delivery.
To date, most licensed vaccines are based on the generation ofneutralizing antibodies which are effective against invariant
antigen-bearing pathogens. However, as antigenic variability in-
creases, the number of licensed vaccines that are effective dramat-
ically decreases (1). As a consequence, HIV-1, a retrovirus with
exceptionally high antigenic variability, may require a completely
novel vaccination strategy. Hence, in an attempt to augment vac-
cine-induced anti-HIV-1 T helper and antibody responses, we
utilized three distinct concepts to formulate a novel immune-
priming paradigm to precede protein boost vaccination. Specifi-
cally, we utilized (i) a DNA plasmid vector called Auxo-GTU,
previously described to induce strong and durable T cell re-
sponses, in combination with (ii) electroporation (EP) and (iii)
concurrent intradermal (i.d.) and intramuscular (i.m.) vaccina-
tions.
The Auxo-GTU technology is a nonreplicating plasmid vector
which utilizes the bovine papilloma virus type 1 (BPV1) transcrip-
tion activator, the segregation/partitioning factor E2 protein, and
itsmultimeric binding sites (2, 3). This has been shown to result in
the enhanced transcriptional activity of the transgenes along with
the potential for increasing the number of cells expressing the
transgene (3). Furthermore, it has previously been utilized in clin-
ical and preclinical studies and has been shown to display a good
safety profile (4). DNA-based vaccination is an attractive mode of
vaccine delivery. DNA vaccines utilize the host for in vivo biosyn-
thesis of transgene products (5), hence imitating infectious path-
ways, and through host cell posttranslational modifications, the
transgene products more accurately represent the conformation
of naturally expressed viral antigens (6). Despite the many advan-
tages, most conventional DNA vaccination strategies appear to be
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poorly immunogenic. Therefore, DNA vaccines have failed to
translate from earlier murine studies to humans, leading to poor
efficacy in human clinical trials (7, 8), and as a consequence, no
prophylactic DNA vaccine is clinically approved for use in hu-
mans (5). To enhance the immunogenicity of DNA vaccines,
strategies such as promoter selection, codon optimization, and
different routes of administration have been employed (5). How-
ever, the delivery ofDNA in associationwith EPhas been shown to
dramatically increase gene expression and vaccine-induced re-
sponses over and above those that have been obtained by the use of
most existing adjuvant technologies (9–12).
Other aspects may play a significant role in the as yet limited
immunogenicity of DNA vaccines. For instance, while most vac-
cinations, includingDNA, are delivered via the i.m. route (13), the
lower number of antigen-presenting cells (APCs) within muscle
tissues has been suggested to be a factor contributing to reduced
efficacy (2, 5, 14). i.m. vaccination has been described to result in
poor antigen-dependent T cell activation owing to the lack of
APCs in muscle tissue (14). Certainly, previous studies have
shown that i.d. vaccination increases the magnitude of polyfunc-
tional CD4 T cell responses compared to that achieved with i.m.
vaccination (15). Therefore, despite myocytes being good trans-
fection candidates (5), the location may be suboptimal for DNA-
based immune activation. As opposed to previously published
findings from studies evaluating single routes of DNA administra-
tion (16), here we report on the use of concurrent multiple-route
vaccination and inoculation i.d., a route that allows the vaccine to
reach a site with a plentiful and diverse number of APCs (17),
combined with concurrent i.m. vaccination. We hypothesized
that this dual-route vaccination may result in enhanced immune
responses to the in vivo-expressed plasmid DNA vaccine trans-
genes. Here we report that combination of the concurrent DNA
vaccination strategy (i.d. [EP] and i.m. [EP]) with a homologous
protein boost vaccination regimen enhances the levels of produc-
tion of antibody with a higher antigen-specific binding avidity.
Furthermore, we show that concurrent DNA priming can aug-
ment the vaccine-elicited T cell response, a factor critical for pro-
viding the necessary T cell help to B cells. Finally, we demonstrate
that the optimized DNA-priming, protein boost regimen can
translate to a larger animal model and drive the production of
neutralizing antibodies against different HIV-1 strains. To our
knowledge, this is the first report of an optimized concurrent par-
enteral approach utilizing DNA EP in a prime-boost regimen to
achieve enhanced immune responses against the HIV-1 envelope.
MATERIALS AND METHODS
Plasmids, protein, and peptides.TheHIV-1 vaccine construct was devel-
oped and prepared using the Auxo-GTU vector technology. The HIV-1
CN54-gp140 clade C/B gene (codon optimized) was inserted into the
Auxo-GTU vector backbone and DNA vaccine produced by Fit Biotech,
Finland. The recombinant CN54-gp140 protein was purchased from
Polymun Scientific (Austria). The gp140-stimulatory peptides, 15-mers
overlapping by 11 amino acids, were devised, synthesized (Insight Bio-
technology, United Kingdom), and split into two pools.
Immunizations. Six- to-8-week old female BALB/c mice (n 8; Har-
lan, United Kingdom) were handled and procedures were performed in
accordance with the terms of a project license granted under the United
Kingdom Home Office Animals (Scientific Procedures) Act 1986. Mice
received three or four plasmid DNA (GTU-CN54-gp140) immunizations
at 3-week intervals as either i.d. (10 g DNA in the lower back), i.m. (50
g in the quadriceps), or i.d. and i.m. combination vaccinations. Injection
sites then received EP using either 5-mm or tweezer electrodes using an
ECM 830 square-wave electroporation system (BTX). Pulses consisted of
100 V of positive and negative polarity at a rate of 1 pulse/s, with each
pulse lasting 50 ms. Protein boost studies involved either two subcutane-
ous (s.c.), intranasal (i.n.), transcutaneous (t.c.), or i.m. protein boosts
(20 g) using the CN54-gp140 protein in the absence of adjuvant. New
Zealand White rabbits (n  8; Harlan, United Kingdom) were handled
and procedures were performed in accordance with the terms of a project
license granted under the United KingdomHome Office Animals (Scien-
tific Procedures) Act of 1986. Rabbits were placed into three groups.
Groups 1 and 2 received three i.d. (EP) and i.m. (EP) DNA-priming vac-
cinations, while groups 1 and 3 received two s.c. recombinant gp140 pro-
tein boost vaccinations. For i.d. and i.m. vaccinations, 20 and 100 g of
DNA were used, while 40 g protein was used for s.c. protein boosts.
Sampling and processing. Blood was collected and centrifuged at
1,000 g for 20 min. The serum was harvested and stored at20°C. To
assess gamma interferon (IFN-) T cell responses, cultures of lympho-
cytes from spleens were prepared as described previously (18, 19).
Bioluminescence imaging. Real-time bioimaging of i.d. and i.m.
DNA vaccinations was performed using a multispectral Carestream in
vivo FX Pro system. Briefly, either 50 g (i.m.) or 30 g (i.d.) GTU-Luc-
GFP plasmid was administered with or without EP to anesthetized
BALB/c mice. Luciferase activity was measured 15 min after i.p. adminis-
tration of D-luciferin (150 mg/kg of body weight; Promega, United King-
dom). Bioluminescence images were acquired and analyzed using Car-
estream software and 60-s exposures.
Immunoglobulin ELISA and avidity assay. A quantitative immuno-
globulin enzyme-linked immunosorbent assay (ELISA) protocol de-
scribed previously (18, 19) was followed. Briefly, 5 g/ml gp140-coated
ELISA plates were blocked with 200 l/well 1% bovine serum albumin
and 0.05% phosphate-buffered saline (PBS)–Tween 20 (PBST). After
washing, samples were diluted and added to the plates for 1 h before
washing and addition of a 1:4,000 dilution of either anti-mouse IgG–
horseradish peroxidase (HRP), IgG1–HRP, IgG2a–HRP, or IgA–HRP
(Southern Biotech). Samples were developed using tetramethylbenzidine
(TMB), and the reaction was stopped using Stop solution (Insight Bio-
technologies, UnitedKingdom). Standards consisted of coatingwith anti-
mouse kappa (1:3,200) and lambda (1:3,200) light chains (Serotec, United
Kingdom), blocking as described above, and then addition of purified IgG
(Southern Biotech, United Kingdom) or IgA (Southern Biotech, United
Kingdom) starting at 200 ng/ml. The absorbance was read on a spectro-
photometer (VersaMax; Molecular Devices) using SoftMax Pro GxP (v5)
software. For the rabbit antigen-specific IgG ELISA, a protocol similar to
that described above was followed. For standards, plates were initially
coated with a 1:1,250 dilution of 2 mg/ml goat anti-rabbit IgG (Millipore,
United Kingdom), followed by 1/5 dilutions of purified rabbit IgG (1,000
ng/ml; Serotec, United Kingdom), and rabbit IgG was detected using
monoclonal anti-rabbit gamma chain-specific IgG (clone RG-96; Sigma,
United Kingdom).
The avidity of serum immunoglobulin was determined by the anti-
body-antigen binding resistance to 8 M urea. Samples were prediluted to
give an optical density (OD) at 450 nm (OD450) readout of between 1.0
and 1.5 and were added to gp140-coated plates. The plates were then
washed three times with either PBST or 8 M urea in PBST, before incu-
bating with anti-mouse IgG–HRP. Samples were developed with TMB as
described above. The avidity index (in percent) was calculated as the
OD450 of urea-treated samples/OD450 of PBST-treated samples. Antisera
with index values exceeding 50% were ascribed a high avidity, those with
index values of 30 to 50% were ascribed intermediate avidity, and those
with index values of30% were ascribed a low avidity.
IFN- antigen-specific ELISpot assays. IFN- enzyme-linked immu-
nosorbent spot (ELISpot) assays (Mabtech, United Kingdom) were car-
ried out on splenocytes per the manufacturer’s instructions and as de-
scribed previously (18, 19). Plates were blocked for 30min using complete
RPMI before addition of 5 106 cells/ml. Next, 5g/ml of gp140 peptide
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pools 1 and 2 was used to stimulate cells for 16 h to assess the responses.
Unstimulated and 5 g/ml phytohemagglutinin (Sigma, United King-
dom)-stimulated cells served as controls. To detect spots, biotinylated
anti-IFN- antibody was added at 1 g/ml for 2 h before washing and
incubatingwith streptavidin-HRP for 1 h. Plateswerewashed as described
above, and 100 l/well of TMB substrate was added.
Virus neutralization assay. HIV-1 serum neutralization assays were
performed using a luciferase-based assay in TZM.bl cells as described
previously (20). Briefly, 3-fold serial dilutions of serum samples in 10%
Dulbecco modified Eagle growth medium (100 l/well) were performed
in duplicate in 96-well plates. A 50-l volume of virus was added to each
well, and the plates were incubated for 1 h at 37°C. TZM.bl cells in growth
medium (1  104 cells/well per 100-l volume) containing 11 g/ml
DEAE-dextran (Sigma) were then added to each well. The neutralization
assay used replicate wells of TZM.bl cells alone (cell control) and TZM.bl
cells with virus (virus control). Following a 48-h incubation at 37°C, a
150-l volume of assay medium was removed from each well and 100 l
of Bright-Glo luciferase reagent (Promega) was added. The cells were
lysed for 2 min, before a 150-l volume of cell lysate was transferred to a
96-well black solid plate, and luminescence wasmeasured using a Victor 3
luminometer (PerkinElmer). The 50% inhibitory dose (ID50) titer was
calculated as the serum dilution that caused a 50% reduction in relative
luminescence units (RLUs) compared to that for virus control wells after
subtraction of cell control RLUs.
Statistical analysis. Statistical analysis of the data was carried out us-
ing aMann-Whitney nonparametric t test and GraphPad Prism software.
RESULTS
Concurrent i.d. and i.m. vaccination with EP enhances cellular
responses as well as alters antibody avidity. i.m. vaccination is
the most common route for DNA vaccination. However, even
though myocytes are highly susceptible to transfection, the re-
sponse obtained by the targeting of muscle tissue for vaccine gene
expression may be limited because of the low number of local
APCs (21). This is in stark contrast to the response obtained by the
targeting of skin, which is notable for its abundance of APCs. We
therefore hypothesized that combining i.m. vaccination with con-
current i.d. vaccination might enhance vaccine-mediated hu-
moral and cellular immune responses over and above the response
normally seen by either route alone. Initially, we compared single-
site i.d. or i.m. vaccination with concurrent i.d. and i.m. vaccina-
tion without EP (see Table S1 in the supplemental material). i.m.
vaccination resulted in significantly (P 0.0009) elevated levels of
antibody in serum compared to those achieved by i.d. vaccination
(Fig. 1a). However, both i.d. and i.m. vaccinations individually
induced nonstatistically distinct IFN- spot-forming unit (SFU)
responses (Fig. 1b), suggesting that individual i.m. vaccinations
were equivalent to i.d. vaccinations for eliciting cellular responses.
When comparing concurrent i.d. and i.m. vaccination with individ-
ual i.d. and i.m. vaccinations, the concurrent i.d. and i.m. vaccination
regimen generated specific IgG concentrations similar to those gen-
erated by i.m. vaccination, and the specific IgG concentrations were
significantly elevated compared to those achieved with i.d. vaccina-
tion (P  0.0019) (Fig. 1a); however, the concurrent regimen in-
creased antibody avidity compared to that achieved by i.m. vaccina-
tion (see Fig. S1a in the supplemental material). Furthermore,
concurrent i.d. and i.m. vaccination significantly enhanced the T cell
responses against peptide pool 1 (P 0.003 andP 0.014 compared
to the responses for the individual i.m. and i.d. vaccination groups,
respectively) and peptide pool 2 (P  0.0379 compared to the re-
sponses for both the individual i.m. and i.d. vaccination groups) (Fig.
1b) relative to the responses seen for the individual i.m. or i.d. vacci-
nation group, indicating that concurrent i.d. and i.m. vaccination is
superior to i.m.vaccinationwith respect toavidity and themagnitude
of cellular responses.
Next, we evaluated the impact of EP on concurrent i.d. and i.m.
vaccination and the relative contribution that EPmade to the cellular
and humoral responses when applied to each vaccination site. All
concurrent vaccination combinations generated equivalent and sig-
nificant concentrations of serum IgG compared to those for the con-
trols (P 0.0005) (Fig. 1c). As all the tested concurrent vaccination
regimenselicited similarantibody titers,weutilizedanavidityassayas
a means to differentiate and qualitatively evaluate the humoral re-
sponses. Here we show that the i.d. (EP) and i.m. group and the i.d.
(EP) and i.m. (EP) group generated the highest proportions ofmedi-
um- and high-avidity responses in serum (Fig. 1f). Strikingly, the i.d.
(EP) and i.m. (EP) regimen generated 50%moremice that serocon-
verted with a high-avidity response than the i.d. (EP) and i.m. regi-
men.This clearlydemonstrates that thedifferent concurrent vaccina-
tion regimens had different impacts on B cell maturation.
Interestingly, significant differences in mucosal IgG responses
were observed. The i.d. and i.m. and the i.d. and i.m. (EP) regi-
mens failed to generate significant quantities of IgG (Fig. 1d).
However, the i.d. (EP) and i.m. (146	 42 ng/ml, P 0.0006) and
the i.d. (EP) and i.m. (EP) (107 	 35.4 ng/ml, P  0.0006) regi-
mens elicited highly significant IgG responses in the vagina com-
pared to those in the control and the i.d. and i.m. groups (P 
0.0024 andP 0.0165, respectively).No significant differencewas
observed between the i.d. (EP) and i.m. and the i.d. (EP) and i.m.
(EP) groups (Fig. 1d), suggesting that administration of EP via the
i.d. route facilitates antibody localization in mucosal secretions.
Evaluation of cellular responses revealed that all concurrent regi-
mens elicited significant T cell responses (P 0.0005) to peptide
pools 1 and 2 compared to the response by the controls (Fig. 1e).
Furthermore, the i.d. (EP) and i.m. and the i.d. (EP) and i.m. (EP)
regimens elicited significantly elevated T cell responses compared
to the i.d. and i.m. and the i.d. and i.m. (EP) regimens for both
peptide pool 1 (P  0.003 and 0.001, respectively) and peptide
pool 2 (P  0.002 and 0.003, respectively). No significant differ-
ences in T cell responses were recorded between the i.d. (EP) and
i.m. and the i.d. (EP) and i.m. (EP) groups (Fig. 1e). Taken to-
gether, these results show the concurrent i.d. (EP) and i.m. (EP)
treatment regimen to be superior for eliciting strong humoral and
cellular responses.
In addition to increasing transgene expression levels, EP has
been described to act as an adjuvant through as yet undefined
mechanisms (22–24). Therefore, using the empty vector, we com-
pared the ability of EP delivered via the i.m. route (see Fig. S2a in
the supplemental material) and EP delivered via the i.d. route (see
Fig. S2b in the supplemental material) to alter antigen-specific
immune responses. Using the empty vector, electroporation via
the i.m. route either augmented or significantly increased cellular
immune responses to the vaccine transgene delivered via the i.d.
route. In contrast, this adjuvant activitywas not observedwhenEP
and empty vector were delivered via the i.d. route. Thus, suggest-
ing that the route of EP delivery can significantly affect the ensuing
cellular immune response.
Concurrent DNA-priming (EP) and protein boost vaccina-
tions enhancehumoral responses.DNApriming and subsequent
protein boosting have been shown to significantly amplify hu-
moral responses. Therefore, we assessed the ability of protein
boost vaccination to augment the antibody responses elicited. We
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FIG 1 Concurrent priming vaccination with EP elicits stronger cellular and higher-avidity antibody responses. (a and b) Single i.d. (10 g) or i.m. (50 g)
vaccinationwas compared to concurrent i.d. and i.m. (10g and 50g) vaccination (n 8mice per group), in the absence of EP, for the elicited antigen-specific
serum IgG antibody (a) and cellular (b) responses. Humoral and cellular responses were evaluated 1 week after the fourth and final vaccination by antigen-
specific IgG ELISA and IFN- ELISpot assay and are shown as group means (	SEM). (c to e) Comparison of the ability of different concurrent vaccination
regimens, in the presence or absence of EP, to elicit antigen-specific serum (g/ml) (c) andmucosal (ng/ml) (d) IgG responses and to stimulate systemic cellular
immunity (numbers of SFU per million antigen-stimulated cells [	SEM]) (e). Mice (n 8 per group) were vaccinated 4 times at 3-week intervals, with bleeds
occurring 1 week after each vaccination.Mucosal sampling occurred during study week 10, 1 week after the final vaccination. Statistical significance was assessed
using the Mann-Whitney U test. *, P 0.05; **, P 0.005; ***, P 0.0005; N.S., not significant. (f) To assess antibody avidity, concurrent vaccination serum
sampleswere prediluted to give an optical density of between 1 and 1.5 using an in-house antigen-specific ELISA. Sampleswere then titrated in an endpoint ELISA
in duplicate using nonreducing (PBS) and reducing (8 M urea) washes after sample addition. Results are shown as the percent change in binding [(reducing
OD/nonreducing OD) 100].
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evaluated the concurrent i.d. (EP) and i.m. (EP) DNA-priming
strategy (here referred to as simply DNA) in combination with
two subsequent protein boost vaccinations via the s.c., i.n., t.c.,
and i.m. routes (see Table S2 in the supplemental material). All
prime-boost regimens generated significantly elevated IgG levels
in the systemic compartment (Fig. 2a). The DNA vaccinations
efficiently primed the immune responses, resulting in elevated
IgG levels in all groups by the end of the 3rd priming (week 6).
These responses were significantly amplified by all routes of pro-
tein boosting. DNA priming boosted by the s.c. (507 	 60.5 g/
ml, P  0.0003) and i.n. (566 	 78.6 g/ml, P  0.0003) routes
generated the highest IgG responses, closely followed by i.m.
boosting (442 	 62 g/ml, P  0.0047). Although the response
was highly significant (119	 30g/ml,P 0.0003), theDNAand
t.c. protein boost regimen resulted in the lowest IgG profile. Se-
rum IgA responses for all boost regimens were also significantly
elevated compared to those for the protein controls (Fig. 2b). The
DNA and i.n. route of protein boost vaccination was clearly supe-
rior to the other boost regimens for the production of antigen-
specific IgA, resulting in highly significant serum IgA concentra-
tions being recorded during study week 13 (3,107 	 1.1 ng/ml,
P 0.0002). The DNA and s.c. (213	 83 ng/ml, P 0.0002) and
DNA and i.m. (196 	 56.7 ng/ml, P  0.0002) routes elicited
similar levels of serum IgA; however, theDNA and t.c. (P 0.029)
regimen resulted in the least antigen-specific IgA being generated
(Fig. 2b). Interestingly, however, the DNA and t.c. route was the
FIG 2 The route of administration of protein boost impacts the ensuing serum humoral responses. (a and b) Antigen (Ag)-specific IgG (a) and IgA (b) from
serum were assessed (n  8 per group) 1 week after three concurrent DNA-priming vaccinations (i.d. [10 g] and i.m. [50 g]) and two protein boosts (20
g/dose). Protein boosts were delivered by either the s.c., i.n., t.c., or i.m. route. Antibody results are expressed as group means (g/ml or ng/ml). Statistical
significance was assessed using theMann-Whitney U test. *, P 0.05; **, P 0.005; ***, P 0.0005. (c) To assess antibody avidity, vaccine serum samples were
prediluted to give an optical density between 1 and 1.5 using an in-house antigen-specific ELISA. Samples were then titrated in an endpoint ELISA in duplicate
using nonreducing (PBS) and reducing (8Murea) washes after sample addition. Results are shown as the percent change in binding [(reducingOD/nonreducing
OD) 100].
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only one that elicited elevated antigen-specific IgA responses after
the final DNA-priming vaccination. Assessment of the serum an-
tigen-specific IgG/IgA ratios revealed that the i.n. boosting route
could dramatically alter the ratio of IgG/IgA, while the t.c. boost-
ing regimen promoted IgG production over IgA production (Fig.
2c.). The i.m. and s.c. routes produced almost equivalent ratios of
IgG/IgA (Fig. 2c.).
The impact of different protein boost vaccination routes on
IgG avidity was assessed in order to ascertain the optimal prime-
boost regimen. Interestingly, the DNA and s.c. route of boost vac-
cination outperformed all other boost regimens, generating the
highest-avidity antibody responses (54.4%) (Fig. 2d). Further-
more, 62.5% of vaccinated animals in the DNA and s.c. group
displayed high-avidity antibody binding, while the remaining an-
imals displayed medium-avidity antibody binding. Interestingly,
while the DNA and s.c. and the DNA and i.n. regimens generated
similar IgG levels (Fig. 2a), the avidities of the elicited antibodies
weremarkedly different (Fig. 2d). A noticeable reduction (15.7%)
in avidity for the DNA and i.n. regimen compared to that for the
DNA and s.c. regimen was recorded, clearly suggesting that the
route of protein boost greatly impacts the quality of the antibody
elicited. Furthermore, it is interesting to note that the DNA and
i.m. (46%) regimen elicited antibody that had an avidity similar to
that of antibody from the non-DNA-primed (46.2%) vaccinated
controls, suggesting that although it is capable of immunologically
priming for large quantities of antibody,DNApriming via the i.m.
route had a minimal impact on B cell maturation (Fig. 2d). Col-
lectively, these results show that the s.c. route of protein boosting
is preferential for the generation of high levels of serum antibodies
with high avidity. The presence of protective antibody in external
mucosal secretions is reasoned to add a significant layer of protec-
tion against HIV-1 infections occurring through susceptible mu-
cosal surfaces. Therefore, we assessed the impact of the different
protein boost vaccination regimens on vaginal antibody re-
sponses. All groups receiving DNA priming and protein boosting
generated significant quantities of IgG in the vaginal vault com-
pared to the quantities for the controls receiving protein only (see
Fig. S3a in the supplemental material). In terms of the elicited
vaginal IgA responses, only the DNA and i.n. protein boost vacci-
nation group generated statistically significant responses (60	 28
ng/ml, P  0.0025) (see Fig. S3b in the supplemental material).
Hence, taken together, these data show that s.c., i.n., t.c., and i.m.
protein boosting significantly augments mucosal IgG antibody
responses, while only the i.n. route significantly increases the pres-
ence of mucosal IgA within external secretions.
The route of protein boost vaccination does not significantly
alter themeanquantity of the vaccine-elicited cellular response.
Next, we evaluated the impact of various routes of protein boost
vaccination on the cellular response of DNA-primed mice. Here
we show that all vaccine regimens which involved prior DNA
priming, DNA and s.c. (840	 184 ng/ml, P 0.0002), DNA and
i.n. (1,113	 188 ng/ml, P 0.0002), DNA and t.c. (1,018	 133
ng/ml, P  0.0002), and DNA and i.m. (692 	 137 ng/ml, P 
0.0002), generated highly significant cellular responses against
peptide pool 1 compared to the responses for their respective con-
trols (Fig. 3a). This was also seen for Env peptide pool 2, when the
results obtained by the DNA and s.c. (595 	 154 ng/ml, P 
0.0009), DNA and i.n. (702	 102 ng/ml, P 0.0002), DNA and
t.c. (1106	 271 ng/ml, P 0.0002), andDNA and i.m. (403	 88
ng/ml, P  0.0002) regimens were compared to those for the
controls (Fig. 3b). Comparisons between the regimens revealed
no statistically significant difference between groups and, there-
fore, no advantage of one protein boost regimenover any other for
augmenting total cellular immune responses.
Concurrent DNA (EP) and s.c. protein boost vaccinations
elicit strong humoral responses and increase antibody avidity
and HIV-1 neutralization in rabbits. The murine model is sub-
optimal for the assessment of neutralizing antibody responses due
to high background levels of nonspecific inhibitor activity. There-
fore, we extended our murine experiments into the larger rabbit
model to test the antibody responses elicited in HIV-1 neutraliza-
tion assays. New Zealand White rabbits were vaccinated using a
triple DNA-priming (i.d. [EP] and i.m. [EP]) regimen followed by
a double s.c. protein boost regimen (see Table S3 in the supple-
mental material). This was chosen on the basis of the observation
that it induced the highest-avidity antibodies in the murine
model. DNA priming utilized concurrent i.d. (20 g) and i.m.
(100g) vaccination and EP followed by homologous s.c. protein
boosting (40 g). The DNA and s.c. regimen (6,697.6 	 2,547
g/ml) elicited higher IgG responses than DNA (99.2 g/ml 	
47.6) or protein alone (100.4	 44.1g/ml) (Fig. 4a), although all
three vaccine regimens, DNA and s.c. (P  0.002), DNA (P  0.
0167), and s.c. (P  0.0167), elicited significant IgG responses
compared to that in baseline control serum. Interestingly, triple
i.d. (EP) and i.m. (EP) DNA vaccination induced antigen-specific
antibody levels similar to those induced by the two s.c. protein
vaccinations.
To better understand the elicited humoral response, we evalu-
ated the avidity of serum from vaccinated rabbits. Here we found
that after two protein boost vaccinations, the avidity index in-
creased for all rabbits that had received priorDNA immunizations
(Fig. 4b), suggesting that B cellmaturation had occurred in rabbits
vaccinated with DNA and s.c. Importantly, this is in agreement
with bilayer interferometry data showing increased binding and
reduced dissociation kinetics (see Fig. S4a in the supplemental
material). Here we found that the first protein boost vaccination
(3.55 103 nm s1) had a 1.45-fold lower rate of change than the
second protein boost vaccination (5.16 103 nm s1), demon-
strating the increased binding kinetics of the serum after each
protein boost. Evaluation of the dissociation rates (Kds) revealed
that after each protein boost vaccination, antibody dissociated
from antigen at a lower rate, indicating increased antibody bind-
ing and, therefore, increased B cell maturation (see Fig. S4b in the
supplemental material).
Next, we evaluated the neutralizing activity of serum from vac-
cinated rabbits in a TZM.bl assay using a variety of tier 1 pseudo-
viruses from clades A, B, and C. Here we found that the DNA and
s.c. vaccination regimen elicited significant neutralizing activity
against clade C MW965.26 (ID50 titer, 7,887.7 	 2,525.6; P 
0.0037), clade B SF162.LS (ID50 titer, 126.5 	 32.2; P  0.014),
and clade A DJ263.8 (ID50 titer, 104	 21; P 0.0037) pseudovi-
ruses compared to that against themurine leukemia virus (MuLV)
negative control (Fig. 4c). Furthermore, theDNAand s.c. regimen
elicited significant neutralizing activity compared to that for the
regimens of DNA alone and s.c. alone for the MW965.26 (P 
0.0022 and P  0.0022, respectively), SF162.LS (P  0.014 and
P 0.0167, respectively), and DJ263.8 (P 0.005 and P 0.005,
respectively) pseudoviruses (Fig. 4c). Therefore, these results
demonstrate the cross-clade neutralizing activity of the DNA and
s.c. vaccination regimen in rabbits.
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Despite the overwhelming success of vaccines, there is a clear re-
quirement for the immediate development of prophylactic inter-
ventions against a number of disease-causing organisms. This is
particularly true for HIV-1, where vaccines are not available and
current vaccine concepts have failed. Hence, novel vaccine tech-
nologies or paradigms will undoubtedly play an important role in
protecting against HIV-1 acquisition. In this study, we used a
DNA plasmid vector expressing gp140 as part of a preclinical
study to deliver HIV-1 Env as a priming vaccine immunogen to
FIG 3 The route of protein boost vaccination does not significantly affect the magnitude of the cellular response. Vaccinated mice (n  8 per group) were
sacrificed 1 week after three concurrent DNA-priming vaccinations (i.d. [10 g] and i.m. [50 g]) and two protein boosts (20 g/dose). Protein boosts were
delivered by either the s.c., i.n., t.c., or i.m. route. Splenocytes were assessed by IFN- ELISpot assay for antigen-reactive T cells using two sets of peptide pools
consisting of 15-mers overlapping by 11 amino acids (a and b). Graphs are expressed as group means (numbers of SFU per million antigen-stimulated cells
[	SEM]). Statistical significance was assessed using the Mann-Whitney U test. ***, P 0.0005.
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two different sites (by the i.d. and i.m. routes) concurrently. The
aim was to elicit through rational vaccine design high-titer anti-
body and cellular responses over and above what is seen through
conventional systemic single-site vaccination. While humoral an-
tibody responses were the principal focus of this study, we also
evaluated gp140-specific cellular responses, as CD4 T cell help is
critical for not only the development of cytotoxic CD8 responses
but also the development of Env-specific high-affinity neutraliz-
ing antibody responses. With that said, the results presented here
clearly demonstrate that concurrent vaccinations are highly effec-
tive activators of both cellular and humoral responses. Of partic-
ular note is the i.d. (EP) and i.m. (EP) combination, which gener-
ated strong T and B cell responses, with the antibody elicited by
this regimen demonstrating a higher avidity than antibody elicited
by all other combinations tested. To our knowledge, this is the first
time that a preclinical vaccination study has evaluated concurrent
plasmid DNA vaccination as part of a prime-boost strategy, and
this study suggests that concurrent DNA vaccine delivery may
offer a new approach in HIV-1 prime-boost vaccine delivery re-
search.
During each stage of evaluation, we selected the best vaccine
combination on the basis of the elicited humoral and cellular re-
sponses. The optimized DNA regimen was then tested in a DNA-
priming, protein boost protocol for any elicited virus-neutralizing
activity. Prime-boost vaccination has previously been used to syn-
ergistically amplify memory T cell responses to vaccinating anti-
gens (25) by invoking CD4 T cells and corresponding T cell-
dependent antibody responses (26). Furthermore, it is believed
that DNA priming can facilitate memory B cell development,
which can be selectively amplified upon recombinant protein
boost vaccination and enhance antibody avidity (26). In this
study, we detected a robust expansion in elicited antibody re-
sponses upon protein boosting in DNA-primed animals, with
maximal affinity maturation being associated with the s.c. route.
Hence, i.d. (EP) and i.m. (EP) vaccination with s.c. protein boost-
ing was found to be the optimal vaccination regimen with respect
to the magnitude and avidity of the systemic IgG responses. Curi-
ously, while the s.c., i.n., and i.m. routes of protein boost vaccina-
tion elicited similar antigen-specific IgG concentrations in serum,
the i.n. route elicited IgG responses which were the lowest in avid-
ity (Fig. 2a and c), suggesting a lack of affinity maturation. This
may be due to suboptimal stimulation of the ensuing immune
responses through a combination of low antigen availability and a
lack of Toll-like receptor activation. It is feasible to assume that i.n.
protein boosting could result in the stimulation of germinal cen-
ters in an alternative repertoire of draining lymph nodes not nor-
mally associated with s.c., i.m., and t.c. vaccination. This could
result in the de novo generation of antibody responses which have
had less time for somatic hypermutation and affinity maturation.
Hence, future studies evaluating the elicited T and B cell responses
for affinity maturation and subsequent epitope breadth, as well as
the impact of various coadministered adjuvants, could prove cru-
FIG 4 Concurrent DNA priming (EP) and recombinant protein boost elicits strong humoral responses with virus-neutralizing activity. (a) Antigen-
specific IgG from serum was assessed (n  6 NWZ rabbits per group) by an in-house ELISA 1 week after either three concurrent DNA-priming
vaccinations (i.d. [20g] and i.m. [100g]) and two protein boosts (40g/dose), three concurrent DNA-priming vaccinations (i.d. [20g] and i.m. [100
g]), or two protein boosts. Antibody results are expressed as group means (	SEM) (g/ml). (b) To assess antibody avidity, rabbit serum samples were
prediluted immediately after DNA priming and after two protein boost vaccinations to give an optical density of between 1 and 1.5 using an in-house
antigen-specific ELISA. Samples were then titrated in an endpoint ELISA in duplicate using nonreducing (PBS) and reducing (8 M urea) washes after
sample addition. Results are shown as the percent change in binding [(reducing OD/nonreducing OD)  100[. (c) TZM.bl virus neutralization assays
were performed on week 13 serum samples using tier 1 pseudoviruses from clades A (DJ263.8), B (SF162.LS), and C (MW965.26) and MuLV as a control.
The ID50 titer was calculated as the serum dilution that caused a 50% reduction in the numbers of RLUs compared to those for the virus control wells
(TZM.bl cells with virus) after subtraction of the number of RLUs for the cell control (TZM.bl cells alone). Statistical significance was assessed using the
Mann-Whitney U test. *, P  0.05; **, P  0.005.
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cial. Using the rabbit as a second animal model, we demonstrate
increased antibody affinitywith each subsequent s.c. protein boost
following optimized DNA priming. This confirmed our earlier
murine studies demonstrating that protein boosting augmented
antibody avidity following prior DNA priming. Interestingly, pre-
vious studies in HIV infection models have correlated increased
antibody avidity with lower viral titers at peak viremia (27), hence
suggesting that B cell antibody maturation can play a protective
role during HIV-1 infection. However, it is important to note that
in previous studies, avidity maturation was ascribed to the use of
adjuvants, such as granulocyte-macrophage colony-stimulating
factor (27). Therefore, as we did not use any immunomodulatory
adjuvant, we associate our increased avidity maturation to the
optimized vaccination protocol.
The production of a neutralizing antibody response has been
the goal for most prophylactic HIV-1 vaccines. This is especially
true since a number of neutralizing antibody-passive infusion
studies provided a proof of concept regarding protection against
infection in the macaque model (28). Furthermore, the appear-
ance of increased polyclonal serum avidity has been shown to
coincide with the appearance of neutralizing antibody responses
(29). However, the broadly cross-neutralizing antibody response
thought to be required for protection against diverse strains of
HIV-1 can take years to develop, if it develops at all (30). Thus, any
vaccination strategy that preferentially drives the development of
affinity maturation or at least speeds up the process may induce
the production of protective neutralizing antibodies. By employ-
ing a sequential experimental process based on avidity, the hu-
moral response, and cellular concentrations, we sought to harness
the elusive vaccine-mediated neutralizing antibody response.
Consequently, critical to our data was the ability of our vaccina-
tion regimen to elicit neutralizing antibody responses. The serum
from the DNA-priming, protein boost group was able to neutral-
ize viruses in both an intraclade and an interclade fashion, indi-
cating that the elicited neutralizing antibody response had a de-
gree of breadth. Currently, there is only one published phase 1
human clinical trial employing DNA-priming, protein boost vac-
cination (31). Within this particular study, the elicited antibody
was capable of neutralizing tier 1 autologous pseudoviruses (31),
hence providing compelling evidence that this type of vaccination
regimen can translate effectively to humans. This is further sup-
ported by DNA-priming, protein boost vaccine regimens that
elicited antibody responses capable of neutralizing homologous
and heterologous viral strains in rhesus macaques (32). More re-
cently, a coimmunization study was evaluated in mice and ma-
caques (33). Here, the authors used a DNA and protein covacci-
nation procedure and plasmids containing a mixture of Env and
Gag DNA delivered by the i.m. (EP) route. The authors also ad-
ministered gp120 protein formulated in EM-005 (glucopyranosyl
lipid adjuvant-stable emulsion) to the same site. Interestingly, the
authors reported that the concurrent regimen enhanced antibody
responses and T cell polyfunctionality and had a broader cross-
clade neutralizing potential (33).
Our current study did not use molecular adjuvants in order to
clearly differentiate the impacts of the different components of the
concurrent regimens.However, it would be interesting to evaluate
the impact of adjuvants on theDNA-priming process aswell as the
protein boost to measure their impact on avidity and neutralizing
potential. This may provide further enhancement, as adjuvants
have been described to drive affinity maturation and promote
antibody avidity against viral antigens (27, 34). As elicitation of
HIV-1 broadly neutralizing antibody responses has been shown to
be coincident with antibody affinity maturation as well as to pos-
sibly be driven by the presence of diverse simultaneously circulat-
ing forms of Env (35), it would be interesting to test the concur-
rent DNA-priming (i.d. [EP] and i.m. [EP]) and s.c. protein boost
regimen with a multiclade vaccine formulation. Therefore, as two
previous human clinical trials (VAX003 and VAX004) involving
bivalent recombinant gp120s adjuvanted with alum have been
shown to elicit tier 1 neutralizing antibody (36, 37), the adjuvana-
tion of our concurrent DNA regimen with s.c. protein boost pres-
ents an intriguing avenue of future investigation. Of particular
note is the use of clade C recombinant gp140 in our studies, while
the VAX003 and VAX004 clinical trials utilized AIDSVAX B/B=
and AIDSVAX B/E. Thus, our preclinical studies demonstrate the
activation of tier 1 neutralization activity against a different
model of Env. Furthermore, as our study was designed with the
augmentation of humoral responses as its principal focus, it
would be interesting to combine this optimized regimen with a
dedicated T cell vaccine strategy. Collectively, the data pre-
sented here support the concept for the use of concurrent
DNA-priming vaccination combinations as mediators of ro-
bust T and B cell responses, with protein boost immunizations
serving to efficiently amplify antibody levels and augment af-
finity maturation and neutralization.
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